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The rapid increase in obesity prevalence in the United States in the last 20 years is unprece-
dented and not well explained. Here, we explore a hypothesis that the obesity epidemic
may be driven by population-wide chronic exposures to low-residue antibiotics that have
increasingly entered the American food chain over the same time period. We propose
this hypothesis based on two recent bodies of published reports – (1) those that provide
evidence for the spread of antibiotics into the American food chain, and (2) those that
examine the relationship between the gut microbiota and body physiology. The livestock
use of antimicrobial agents has sharply increased in the US over the same 20-year period
of the obesity epidemic, especially with the expansion of intensified livestock production,
such as the concentrated animal feeding operations. Observational and experimental stud-
ies support the idea that changes in the intestinal microbiota exert a profound effect on
body physiology. We propose that chronic exposures to low-residue antimicrobial drugs in
food could disrupt the equilibrium state of intestinal microbiota and cause dysbiosis that
can contribute to changes in body physiology. The obesity epidemic in the United States
may be partly driven by the mass exposure of Americans to food containing low-residue
antimicrobial agents. While this hypothesis cannot discount the impact of diet and other
factors associated with obesity, we believe studies are warranted to consider this possible
driver of the epidemic.
Keywords: obesity, antibiotic residues, intestinal microbiota, food chain, CAFOs, animal husbandry, polysaccharide
diet
INTRODUCTION
Obesity in non-elderly adults is defined as a body mass index
(BMI=weight in kilograms divided by height in meters squared)
of 30 or higher (1). Obesity has emerged as an epidemic, espe-
cially in the United States, accompanied by a variety of chronic
medical problems, including diabetes, hypertension, and dyslipi-
demia. In the United States, the increase in overweight and obesity
prevalence has particularly accelerated in the last 20 years. The
overweight prevalence doubled from a mean of 15.1% in 1976–
80 to 31.2% in 2001–2004 (2). In 2000, none of the states had
an obesity prevalence exceeding 30%; by 2010, 12 states reported
an obesity prevalence of >30% (3). Although the prevalence
appears to be leveling off, it had increased to 35.7% among adults
by 2009–10 (4). A Centers for Disease Control and Prevention
(CDC) survey of 3141 counties in the US in 2007 revealed dis-
tinct geographic clustering of obesity prevalence, with the highest
prevalence (>30.9%) occurring in the Southeastern states and in
the Appalachian counties of Tennessee and Kentucky (5).
Many putative causes of obesity and its epidemic in the US have
been suggested (6). Most reports attribute the obesity epidemic to
factors such as excess food energy intake, changes in diet and eating
behavior, and increasing sedentary life style. Undoubtedly, these
factors contribute, but can they all account for the rapid increase
in this problem that occurred over the last two decades? Recently,
a series of experimental and observational studies have described
the role and impact of intestinal microbial population structure
(microbiota) on body metabolism and energy balance, and how its
disruption (dysbiosis) could adversely affect body physiology and
health (7–9). If such a mechanism – disruption of the intestinal
microbiota – occurred at the population level, it could potentially
explain the obesity epidemic.
As with infectious disease epidemics, the obesity epidemic
affecting large segments of a population within a short time frame
suggests common population-wide exposures. What such com-
mon exposures could alter the gut microbiota at the population
level? Here, we review a body of literature to support a hypothesis
that the American human intestinal microbiota may have been dis-
rupted by chronic, widespread exposures to antimicrobial residues
that have increasingly entered our food chain and the environment
over the last 20 years. These exposures may be contributing to the
obesity epidemic.
Our hypothesis is based on review of relevant literature, per-
formed as follows. We first searched PubMed by cross-referencing
the word “obesity” with the following terms: epidemic, prevalence,
diet, calorie intake, nutrients, physical activity, lifestyle, host fac-
tors, genetics, antibiotics/antimicrobial agents, antibiotic residues
in food, antibiotics in plants, antibiotic growth promoters, envi-
ronmental release of antibiotics, animal husbandry, animal feed,
gut microbiome/microbiota, and metagenome. We then found
additional references by reviewing the cited references from the
primary articles. We excluded abstract reports or conference pro-
ceedings. Articles not available electronically were sought at the
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University of California library collections. The search was limited
to publications in English up to August 2013.
ANTIBIOTICS IN THE ENVIRONMENT AND FOOD
What is the evidence that American food contains antimicrobial
agents or that food can become contaminated with them? One
major potential source of antibiotics that enter the food chain in
the US is the food animal reservoir. The intensification in live-
stock production and animal feeding operations (AFOs) greatly
expanded in the 1990s, which also greatly expanded the therapeu-
tic and prophylactic use of antibiotics (10). In the US, at least 17
classes of antimicrobial agents are approved for use in animal hus-
bandry (11). The estimates of antibiotic use in food animals prior
to 2008 are not readily obtainable, but various sources report the
use in the US to range from 20.5 million pounds for all purposes
in 1999 (12) to 24.6 million pounds a year for non-therapeutic
purposes alone (13). An Institute of Medicine report in 1989 esti-
mated that more than 50% of all antimicrobial agents produced in
the US are used for livestock (14). The Food and Drug Adminis-
tration (FDA) reported that in 2011, the sales and distribution of
antimicrobial agents approved for use in food-producing animals
were 13,542,030 kg (15), which is about four times the total sold
and distributed for use to treat human infections (15). Chlortetra-
cycline alone had the highest annual estimated use at 533,973 kg
just for swine production in the US (16).
About 75% of antibiotics given to feedlot animals are not
absorbed by the body and hence excreted in waste (manure and
urine) (17, 18). In 2002, 185 million swine sold in the US generated
about 280 million tons of fresh manure; in 2006, chicken produced
even more (460 million tons), while, in 2007, beef cattle produced
3.6 million tons of manure (19–21). Environmental pollution
from animal waste results from direct discharges, open feedlots,
pastures, storage lagoons, stockpiles, and land application fields.
Manure is converted into fertilizers and spread over crops. From
these sources, contamination can occur on surface water, ground-
water, and soil. Based on the amount of antibiotics estimated to be
used for growth promotion in animal husbandry, 7.5–18 million
pounds of these antimicrobial drugs could be released into the
environment annually (12, 13).
In the last 20 years, the above practices as well as the shift
from integrated farming operations to concentrated animal feed-
ing operations (CAFOs) have led waste-related pollution to be
concentrated in certain geographic regions of the US (18). The
largest increase in broiler chicken CAFOs occurred in the South-
eastern states in the last 20 years (22) – practically overlapping with
the counties with the highest obesity prevalence in the US (5).
Antibiotics released into the environment have varied
biodegradability, depending on their chemical property, soil com-
position, climactic conditions, and other environmental factors
(10). Some antibiotics released into soil by manure may be detected
up to 5 months (23). Yang and Carlson analyzed tetracyclines and
sulfonamides along the Cache la Poudre River in Colorado, and
found that while no drugs were found in the pristine, mountain
stretch of the river, sulfonamides were found along the remain-
ing stretch and tetracycline concentrations progressively increased
downstream from urban areas (24). The tetracycline concentra-
tions correlated with agricultural activity (24). In another study
of 139 streams sampled in the US between 1999 and 2000,
trimethoprim, erythromycin, lincomycin, and sulfamethoxazole
were detected in more than 15% of the samples (25).
Antibiotics can also accumulate in plant tissue. Dolliver et al.
showed experimentally that sulfamethazine in manure-amended
soil accumulated in corn, lettuce, and potato at concentrations of
0.1–1.2 mg/kg dry weight (26). Others have shown accumulation
of low concentrations of antibiotics in carrot roots, green onion,
and cabbage (23, 27).
In addition to livestock sources, antimicrobial agents are
released into the environment from aquaculture (e.g., shrimp and
fish farms) (28–30), spraying fruit orchards and vegetables (31,32),
and from discarded expired drugs, hospital effluents, and other
human activities (33). Thus, there is ample evidence that antibi-
otics can enter our food chain from a variety of sources, and that
humans are chronically exposed to these drugs (Table 1). These
exposures have greatly increased in the US in the last 20 years,
overlapping closely both in time and place with the increasing
prevalence of obesity.
Of course, we acknowledge that exposure does not necessar-
ily indicate cause and effect, and the evidence to date showing
the association is largely ecologic. Furthermore, the impact of
changes in dietary intake that also took place in the US in the
last 20 years cannot be completely discounted. The average per
capita per day energy levels available in the US food supply was
3,400 kcal in 1909–1919, 3,600 kcal in 1990–1999, and 3,900 kcal
in 2004 (59). National Center for Health Statistics through series
of surveys (National Health Examination Surveys from 1959 to
1970 and the National Health and Nutrition Examination Surveys
from 1971 to 2004) shows that the prevalence of overweight and
obese Americans increased slowly through the middle of 1970s
and then sharply began to rise thereafter (2). Thus, the period of
accelerated increase in weight gain overlaps with both increased
dietary caloric intake and antibiotic exposures in food. Here, we
argue that the effect of diet and exposure to low-residue antibi-
otics in food on weight gain may be related and that they cannot
be easily disassociated. We provide below the biological plausibil-
ity evidence for how antibiotics may influence body physiology
and how diet contributes to this effect in ways that had not been
previously considered.
ANTIBIOTICS AS GROWTH PROMOTERS
In 1946, Moore et al. reported that the administration of low-dose
streptomycin and sulfasuxidine in chicken feed caused increased
weight gain in chicks (60). Stokstad et al. reported in 1949 that
chlortetracycline-containing mash had a growth-promoting effect
on poultry (61). In 1950, Luecke et al. reported that strepto-
mycin in combination with vitamin B12 included in a basal diet
caused 40% weight gain in pigs (62). These and other similar
observations led the food animal industry to gradually adopt the
practice of administering subtherapeutic doses of antibiotics as
growth promoters and to enhance feed efficiency (63, 64). Debate
concerning the economic benefits versus health hazards of this
practice began in the 1960s and continues to this day (64–72).
Much of the debate has focused on whether or not this practice
contributes significantly to the selection of pathogens that cause
human drug-resistant infectious diseases. Here, we propose a new
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Table 1 | Food, water, and environmental sources found to contain residues of antimicrobial agents.
Source Antimicrobial agents found Concentrations Country Reference
FOOD
Shrimp Fluoroquinolones 0.1–1 ng/g USA (28)
Salmon, trout, shrimp tissues Fluoroquinolones 0.28–16 ng/g Canada (29)
Swine, chicken, shrimp tissues Fluoroquinolones 1–100 ng/g China (34)
Bob veal, heavy calves, heifers, market hogs,
non-formula-fed veal, roaster pig, sows
Sulfonamides 0.1–1 ppm USA (35)
Bull meat Moxidectin (milbemycin) 89.13 ppb USA (35)
Goat meat Oxytetracycline 4.66 ppm USA (35)
Market hog, roaster pig meat Carbadox 47–110 ppb USA (35)
Catfish, basa Fluoroquinolones 1.9–6.5 ppb China (36)
Honey Erythromycin 50–1776 ng/g Turkey (37)
Corn, green onion, cabbage Chlortetracycline 2–17 ng/g USA (27)
Pig farm waste water Sulfonamides 20µg/mL Vietnam (38)
Sewage samples Cefalexin, cefotaxime >1µg/mL Hong Kong, Shenzhen (39)
Swine farm lagoon Chlortetracycline 68–1000µg/L USA (40)
Wastewater treatment plant effluent Minocycline, epitetracycline,
tetracycline, doxycycline
95.8–915.3µg/L Portugal (41)
Wastewater treatment plant final effluents Erythromycin, ciprofloxacin,
sulfamethoxazole, tetracycline
0.08, 0.118, 0.243,
0.151µg/L
Canada (42)
Wastewater Chlortetracycline, ciprofloxacin,
erythromycin, sulfamethoxazole,
tetracycline, trimethoprim
0.69, 0.03–0.14, 0.9–1.7,
0.05–1.9, 0.05–0.85,
0.05–0.71µg/L
USA (25, 43)
Cache la Poudre River Macrolides 0.06–0.17µg/L USA (44)
Wastewater Sulfamethoxazole 232–9000 ng/L Austria, Switzerland,
USA, Spain, Germany
(45)
Elbe and Saal rivers Erythromycin, sulfamethoxazole,
trimethoprim
30–70, 30–70,
<30–40 ng/L
Germany (46)
Po river Macrolides 0.7–68.3 ng/L Italy (47)
Wastewater treatment plant effluents Quinolones 40–580 ng/L France, Italy, Sweden,
Greece, Switzerland
(48, 49)
Wastewater treatment plant effluent Sulfamethoxazole, trimethoprim,
ofloxacin, erythromycin
310–400, 180–320,
110 ng/L, 2.5µg/L
USA, Germany (50, 51)
Rio Grande river Sulfamethoxazole 300 ng/L USA (51)
Surface water Erythromycin, sulfamethoxazole 150, 30 ng/L Germany (50)
Cattle manure Chlortetracycline 7.73 mg/L USA (52)
Cattle, turkey manure Monensin 1–4.4, 1.2–1.5 mg/L USA (53)
Swine manure Chlortetracycline 27 mg/L USA (54)
Swine slurry Tetracycline 5–24 mg/L Germany (55)
(Continued)
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Table 1 | Continued
Source Antimicrobial agents found Concentrations Country Reference
OTHERS
Hospital effluent sludge Oxofloxacin, ciprofloxacin 0.7–2.0 mg/kg Sweden (56)
Hospital effluent Ciprofloxacin, ampicillin 0.7–124.5, 20–80µg/L Germany (57)
Hospital effluent Minocycline, epitetracycline,
tetracycline, doxycycline
8.1–531.7µg/L Portugal (41)
Hospital effluent Ciprofloxacin, metronidazole,
sulfamethoxazole, trimethoprim,
doxycycline
3.6–101, 0.1–90.2,
0.4–12.8, 0.6–7.6,
0.6–7.6µg/L
Sweden (58)
Hospital effluent Sulfamethoxazole, trimethoprim,
ofloxacin, ciprofloxacin,
lincomycin, penicillin G
400–2100,
2900–5000 ng/L,
25.5–35.5µg/L,
850–2000, 300–2000,
850–5200 ng/L
USA (51)
Dairy plant effluent Lincomycin 700–6600 ng/L USA (51)
hypothesis that this practice may also contribute to the human
obesity epidemic.
Several hypotheses to explain the mechanism of weight gain
in antibiotic-fed animals have been proposed: (1) suppression of
subclinical infections and overt diseases which promotes general
health of the animal and hence better nutrition, (2) stimulation of
growth of bacteria in the gut that synthesize essential nutrients, (3)
suppression of microbes that compete with the host for nutrients,
and (4) improvement in intestinal absorption of nutrients (73, 74).
The possibility that humans are exposed to subtherapeutic
doses of antibiotics led Ternak to first propose in 2004 that human
exposure to low-dose antibiotics may be contributing to weight
gain in humans (75). Raoult in 2008 proposed that the gut micro-
biota modifiers, such as antibiotics and probiotics used in animal
husbandry as growth promoters, may contribute to human body
weight gain (76). Thus, if humans are indeed chronically exposed
to low-dose antibiotics from the environment, there is a good
reason to believe that they too can gain weight.
CHANGE IN INTESTINAL MICROBIAL POPULATION
STRUCTURE AND ITS EFFECT ON BODY PHYSIOLOGY
A recent series of reports has shown that the structure of the total
human intestinal microbial population (microbiota) has a pro-
found influence on body physiology (8, 77–89). The total number
of bacterial cells in the human intestine (~100 trillion) is estimated
to exceed the total number of somatic and germ cells of the human
body by 10-fold (90). Thus, the gut microbiota requires an external
supply of energy and nutrients for its own long-term residence in
the intestine. It also has to share these nutrients with the human
body. In fact, this homeostatic competition, if not disrupted, ben-
efits the host in many different ways. The gut microbiota may even
be considered as another vital human organ.
Anaerobic bacterial species that ferment dietary polysaccha-
rides produce short-chain fatty acids (SCFAs) that are taken up by
the host as an energy source (91). It is estimated that ~4–10% of
the food energy intake of the human body, or 80–200 kcal/day, is
derived from these SCFA produced by colonic bacterial fermenta-
tion (92, 93). Other bacterial populations produce vitamins (e.g., B
and K) and amino acids essential for the host (94). The microbiota
also protects the host against pathogens by competitive exclusion
(95). Finally, it is needed for the proper development of the intesti-
nal immune system (96, 97). Over a course of tens of thousands
of years, the intestinal bacterial population evolved with the Homo
sapiens body to share and compete for energy and nutrient supply
and, in the process, has come to establish a stable equilibrium state.
This intestinal microbial equilibrium state contributes to home-
ostatic maintenance of body weight. A disruption of this steady
state (dysbiosis) could affect nutrient and energy utilization by
the human body and therefore its physiology.
The human gut microbiota is predominantly composed of four
bacterial phyla – Firmicutes, Bacteroidetes, Actinobacteria, and
Proteobacteria, with the first two accounting for about 90% of the
gut phylotypes (98). Cultivation-independent methods (e.g., 16S
rDNA sequence analysis) have revealed that the total number of
bacterial species in the gut could be in the range 15,000–36,000
(99). The largest number of bacteria is found in the colon with
up to 1011 microorganisms/gram of feces (100). A study of 22
samples of intestinal microbiomes from four countries identified
three predominant clusters (enterotypes) that differ in species and
functional composition, independent of nation or continent (101).
Studies of mammalian host gut microbiota have shown that its
alteration can affect body weight (7, 77–79, 81–83, 85). The impact
of dysbiosis on obesity and metabolic disorders has been recently
reviewed in detail by Harris et al. (9). Backhed et al. first reported
that conventionally reared (CONV-R) mice fed polysaccharide-
rich diet weighed about 40% more than its germ-free (GF) coun-
terpart fed the same diet (77). When the gut microflora from the
CONV-R mice was transferred to the GF mice, the latter under-
went a 60% weight gain in 2 weeks (77). The increase in weight
of the lean mice was attributed to the gut microflora that allowed
energy to be salvaged from otherwise indigestible polysaccharide
diet. Ley et al. have shown that obese mice, due to a homozygous
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mutation in the leptin gene (ob/ob), have a 50% reduction in
the Bacteroidetes population with a proportional increase in Fir-
micutes (102). Turnbaugh et al. reported that a transfer of the
microbiota from obese mice to GF mice resulted in greater increase
in total body fat in the latter (7).
Differences in gut microbiota have also been documented in
obese versus lean human subjects (8, 80, 86, 87). One study char-
acterized the fecal microbial communities of obese and lean pairs
of adult female monozygotic and dizygotic twins and their mothers
and found that obesity was associated with phylum-level changes
in the microbiota and reduced bacterial diversity (8). A study
by Schwiertz et al. showed that rather than Firmicutes, increased
Bacteroidetes to Firmicutes population ratio was associated with
obesity (88). Ley et al. followed obese subjects on weight-reducing
diet for 1 year and found Bacteroidetes proportion to increase rel-
ative to Firmicutes (80). Other authors have observed that weight-
reducing diets in obese subjects can alter the gut microbiota species
composition, but no major changes in the ratio of Bacteroidetes to
Firmicutes between lean and obese subjects were found (84). The
study that examined the three enterotypes of human gut micro-
biota did not find any correlation between Bacteroidetes/Firmicute
ratio and BMI (101). Jumpertz et al. prospectively measured
ingested and stool calories of lean volunteers, and found that a
20% increase in Firmicutes with a corresponding decrease in Bac-
teroidetes correlated with an increased energy harvest of ~150 kcal
(103). The above studies that compared intestinal microbiomes
at the phylum-level show mixed and conflicting results. However,
when the intestinal microbiota is examined at the functional group
level, correlations with host characteristics begin to be revealed.
Several studies have found that obese mice and human subjects
have a larger amount of SCFA in their stool than do lean indi-
viduals (7, 82, 88). Arumugam et al. reported that while the three
human gut enterotypes did not show any correlation with BMI,
there was strong correlation between F-type ATPase abundance
and increasing BMI (101). Cani et al. showed that lipopolysac-
charide purified from E. coli injected subcutaneously into mice
induced obesity as well as insulin resistance (82).
Another report showed that endotoxin-producing Enterobac-
ter given to GF mice on high-fat diet became obese, while control
GF mice fed the same diet did not gain weight (104). Mice given
Enterobacter and normal mouse chow did not gain weight. The
Enterobacter was obtained from a morbidly obese volunteer sub-
ject, whose intestinal microbiota was largely (35%) comprised
of this bacterial genus (104). With shift to a diet comprised of
whole grain and traditional Chinese medicinal food, the volun-
teer’s weight decreased>57 kg after 23 weeks, and the Enterobacter
population decreased to 1.8% of the intestinal microbiota (104).
Indeed, Zhang et al. recently reported that in mice, diet changes
explained 57% of the population variation in the intestinal micro-
biota, whereas genetic mutation accounted for no more than
12% (105).
More recently, Ridaura et al. transplanted fecal microbiota from
human monozygotic twins discordant for obesity into GF mice and
showed that mice given the microbiota from the obese member of
the twin increased in adiposity (89). Then, mice transplanted with
fecal microbiota from the co-twins were cohoused. Mice given
obese co-twins’ microbiota were prevented from gaining adiposity
when cohoused with mice given lean co-twins’ microbiota (89).
This transformation was associated with invasion of Bacteroidales
from lean into obese microbiota. Mass spectrometry analysis of
sera revealed significant increases in branched chain amino acids
in mice that received fecal microbiota from obese co-twins, while
the microbiota transplanted from lean co-twins exhibited a sig-
nificantly higher expression of genes involved in plant-derived
polysaccharides and a higher concentration of SCFAs (butyrate
and propionate)(89). These observations demonstrate that the
interactions between diet and gut microbiota can influence body
physiology. Such interactions can certainly be profoundly affected
by antibiotics.
The next relevant question would be, how does exposure
to antibiotics contribute to alteration in intestinal microbial
population?
EVIDENCE OF ANTIBIOTIC-INDUCED CHANGES IN THE
HUMAN GUT MICROBIOTA AND BODY PHYSIOLOGY
The intestinal microbiota serves as an interface between the human
body and its environment. Its perturbation is bound to affect body
physiology. We argue that low-dose antibiotics in food are a major
contributor to this perturbation. The analysis of the intestinal
microbiota or body physiology in humans exposed to antibiotics
has been largely confined to those studies of subjects receiving
therapeutic drug doses. Blaser and Falkow have suggested that the
accelerated disappearance of the normal human microbial com-
munity, such as Helicobacter pylori in the stomach, due in part to
the human use of antibiotics to treat peptic ulcer disease, may be
contributing to post-modern conditions, including obesity (106).
In a 10-month prospective experimental study of three human
subjects given two courses of ciprofloxacin, Dethlefsin and Rel-
man showed that the gut microbiota was rapidly altered with the
antimicrobial drug exposure (107). The composition of the micro-
biota stabilized after 10 months, but in an altered state (107). A
study in France of patients with infective endocarditis showed that
a 6-week treatment course with vancomycin and gentamicin, but
not other antibiotics, was associated with a significant increase in
BMI among males >65 years of age (108). Trasande et al. exam-
ined the long-term effect of antibiotic exposures in the first 2 years
of life of children born in Avon, United Kingdom between 1991
and 1992 (109). They found that exposure to antibiotics during
the first 6 months of life, but not during 6–14 or 15–23 months
was consistently associated with a later increase in BMI (109).
Thus, even short-term exposures to antibiotics appear to have
an effect on BMI in humans. If indeed, a large proportion of
Americans are exposed to low-residue antibiotics in the food they
eat, chronic exposures to such sources could certainly disrupt the
normal steady state gut microbiota, which should be reflected by
changes in body physiology that occur at the community and pop-
ulation level. It is interesting to note that adult obesity prevalence
increased only slightly from the 1950s through the mid-1970s
(involving cohort of people born in the 1930–50s, who would
have had no or low-dose exposure to antibiotics in food) (2).
The sharp rise began after the 1970s, with the greatest increase
occurring after 2000, when obesity among children and teenagers
also had the greatest increase (4) (involving cohort of people born
during the period of sharpest increase in CAFOs and other forms
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of intensified livestock production and AFOs). These population-
based data do not show a causal effect, but the fact that low-dose
antibiotics do cause weight gain in food animals provides a strong
rationale to examine the effect of this type of exposure at the
human population level.
FUTURE RESEARCH
This new hypothesis raises several research questions. To date,
the demonstration of the link between intestinal microbiota with
changes in body physiology has been experimental, involving mice
or selected human subjects. The impact of antibiotic exposures
on the gut microbiota ecology and body physiology needs to be
examined at the population level. The comparison of gut micro-
biota of populations residing near CAFOs versus those living away
from such places may reveal microbiota population structures
associated with differences in body physiology. Antibiotic con-
centrations in the water and food these populations ingest could
be measured for some class of drugs. Serial analysis of the gut
microbiome of children at risk for weight gain followed prospec-
tively may reveal changes associated with weight gain. Clearly,
obesity has multifactorial causes. Prospective, population-based
studies can be conducted to determine the relative proportion
of the obesity prevalence that may be contributed by antibiotic
exposure in food, if any. Obesity prevalence is also increasing in
other countries, especially in the emerging economy nations. The
practice and trend of use of antibiotics as growth promoters in
animal husbandry can be assessed to examine the relevance of this
hypothesis to the obesity epidemic in these other regions of the
world. Finally, a more systematic and comprehensive analysis of
antimicrobial residues in food and the environment is needed.
CONCLUSION
There is accumulating evidence that changes in gut microbiota
can affect body physiology. While the exact mechanism remains
unsolved, animal experimental and human observation studies
provide tantalizing evidence that these changes in the intestine
can be triggered by exposures to antimicrobial agents, especially
in the context of certain dietary nutrients introduced into the gut,
and that these changes can contribute to weight gain. What has
been lacking is the epidemiologic evidence in support of this idea.
Today, the core gut microbiota of many Americans may be sub-
stantially different from that of most Americans living before the
1950s. We propose this idea to be considered to explain part of the
obesity epidemic in the US. Clearly more observational as well as
experimental studies are necessary to support the hypothesis.
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